The occurrence and fate of pharmaceutical and personal care products in the environment are of increasing public importance because of their ubiquitous nature and documented effects on wildlife, ecosystems, and potentially humans. One potential, yet undefined, source of entry of pharmaceuticals into the environment is via the land application of municipal wastewater onto permitted lands. The objective of the present study is to determine the extent to which pharmaceuticals are mitigated by or exported from managed tree plantations irrigated with municipal wastewater. A specific focus of the present study is the presence of pharmaceutical compounds in groundwater and surface water discharge. The study site is a municipality that land-applies secondary treated wastewater onto 930 hectares of a 2000-hectare managed hardwood and pine plantation. A suite of 33 pharmaceuticals and steroid hormones was targeted in the analysis, which consisted of monthly grab sampling of groundwater, surface water, and wastewater, followed by concentration and cleanup via solid phase extraction and separation, detection, and quantification via liquid chromatography coupled with tandem mass spectrometry. More than one-half of all compounds detected in irrigated wastewater were not present in groundwater and subsequent surface water. However, antibiotics, nonsteroidal anti-inflammatory drugs, caffeine, and other prescription and over-the-counter drugs remained in groundwater and were transported into surface water at concentrations up to 10 ng/L. These results provide important documentation for pharmaceutical fate and transport in forest systems irrigated with municipal wastewater, a previously undocumented source of environmental entry.
Background: The damaging effects of exposure to environmental toxicants differentially affect genetically distinct individuals, but the mechanisms contributing to these differences are poorly understood. Genetic variation affects the establishment of the gene regulatory landscape and thus gene expression, and we hypothesized that this contributes to the observed heterogeneity in individual responses to exogenous cellular insults. Objectives: We performed an in vivo study of how genetic variation and chromatin organization may dictate susceptibility to DNA damage, and influence the cellular response to such damage, caused by an environmental toxicant. Materials and Methods: We measured DNA damage, messenger RNA (mRNA) and microRNA (miRNA) expression, and genome-wide chromatin accessibility in lung tissue from two genetically divergent inbred mouse strains, C57BL/6J and CAST/EiJ, both in unexposed mice and in mice exposed to a model DNA-damaging chemical, 1,3-butadiene. Results: Our results showed that unexposed CAST/EiJ and C57BL/6J mice have very different chromatin organization and transcription profiles in the lung. Importantly, in unexposed CAST/EiJ mice, which acquired relatively less 1,3-butadiene-induced DNA damage, we observed increased transcription and a more accessible chromatin landscape around genes involved in detoxification pathways. Upon chemical exposure, chromatin was significantly remodeled in the lung of C57BL/6J mice, a strain that acquired higher levels of 1,3-butadiene–induced DNA damage, around the same genes, ultimately resembling the molecular profile of CAST/EiJ. Conclusions: These results suggest that strain-specific changes in chromatin and transcription in response to chemical exposure lead to a "compensation" for underlying genetic-driven interindividual differences in the baseline chromatin and transcriptional state. This work represents an example of how chemical and environmental exposures can be evaluated to better understand gene-by-environment interactions, and it demonstrates the important role of chromatin response in transcriptomic changes and, potentially, in deleterious effects of exposure. https://doi.org/10.1289/EHP1937
Novel Rho kinase (ROCK) inhibitors were tested for attenuation of airway hyperreactivity (AHR) and pulmonary inflammation. Two distinct profiles of molecules were explored: orally bioavailable molecules, represented by INS117758, suitable for oral product development; and orally nonbioavailable molecules, represented by INS117509, suitable for development as an inhaled product with limited systemic exposure. INS117758 and INS117509 potently inhibit ROCK2 (K i values of 3.8 and 3.3 nM, respectively). While INS117758 is orally bioavailable in rats following 10 mg/kg p.o. dosing (C max = 5.6 μM, T max = 0.83 hours, T 1/2 = 1.55 hours), INS117509 was not detectable in rat plasma following p.o. dosing. INS117758 and INS117509 relaxed carbachol‐precontracted tracheal rings (242 nM and 103 nM IC 50 s, respectively). Dosing of INS117758 p.o. at 5 mg/kg and INS117509 intratracheally (i.t.) at 1.5 mg/kg fully reversed AHR and reduced eosinophilia in OVA‐sensitized mice and neutrophilia in LPS‐exposed mice. In conclusion, Inspire novel ROCK inhibitors are suitable for treatment of respiratory diseases with AHR and pulmonary inflammation via oral route of delivery as well as inhaled route of delivery with limited systemic exposure. Funded by Inspire Pharmaceuticals.
The formation of methylarsonous acid (MAsIII) and dimethylarsinous acid (DMAsIII) in the course of inorganic arsenic (iAs) metabolism plays an important role in the adverse effects of chronic exposure to iAs. High-performance liquid chromatography-inductively coupled plasma-mass spectrometry (HPLC-ICP-MS) and hydride generation-cryotrapping-atomic absorption spectrometry (HG-CT-AAS) have been frequently used for the analysis of MAsIII and DMAsIII in biological samples. While HG-CT-AAS has consistently detected MAsIII and DMAsIII, HPLC-ICP-MS analyses have provided inconsistent and contradictory results. This study compares the capacities of both methods to detect and quantify MAsIII and DMAsIII in an in vitro methylation system consisting of recombinant human arsenic (+3 oxidation state) methyltransferase (AS3MT), S-adenosylmethionine as a methyl donor, a non-thiol reductant tris(2-carboxyethyl)phosphine, and arsenite (iAsIII) or MAsIII as substrate. The results show that reversed-phase HPLC-ICP-MS can identify and quantify MAsIII and DMAsIII in aqueous mixtures of biologically relevant arsenical standards. However, HPLC separation of the in vitro methylation mixture resulted in significant losses of MAsIII, and particularly DMAsIII with total arsenic recoveries below 25%. Further analyses showed that MAsIII and DMAsIII bind to AS3MT or interact with other components of the methylation mixture, forming complexes that do not elute from the column. Oxidation of the mixture with H2O2 which converted trivalent arsenicals to their pentavalent analogs prior to HPLC separation increased total arsenic recoveries to ~95%. In contrast, HG-CT-AAS analysis found large quantities of methylated trivalent arsenicals in mixtures incubated with either iAsIII or MAsIII and provided high (>72%) arsenic recoveries. These data suggest that an HPLC-based analysis of biological samples can underestimate MAsIII and DMAsIII concentrations and that controlling for arsenic species recovery is essential to avoid artifacts.
